KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Capital Leases (2023 - 2025)

Aquestive Therapeutics has reported Capital Leases over the past 3 years, most recently at $122000.0 for Q3 2025.

  • For Q3 2025, Capital Leases fell 20.26% year-over-year to $122000.0; the TTM value through Sep 2025 reached $122000.0, down 20.26%, while the annual FY2024 figure was $146000.0, 15.61% down from the prior year.
  • Capital Leases for Q3 2025 was $122000.0 at Aquestive Therapeutics, down from $130000.0 in the prior quarter.
  • Over five years, Capital Leases peaked at $173000.0 in Q4 2023 and troughed at $122000.0 in Q3 2025.
  • A 3-year average of $148625.0 and a median of $149500.0 in 2024 define the central range for Capital Leases.
  • Biggest five-year swings in Capital Leases: dropped 15.61% in 2024 and later dropped 20.26% in 2025.
  • Year by year, Capital Leases stood at $173000.0 in 2023, then decreased by 15.61% to $146000.0 in 2024, then fell by 16.44% to $122000.0 in 2025.
  • Business Quant data shows Capital Leases for AQST at $122000.0 in Q3 2025, $130000.0 in Q2 2025, and $138000.0 in Q1 2025.